Thursday May 2
Post-IPO Strength Seen In Stemline Therapeutics
Investor demand for shares of Stemline Therapeutics seems to be picking up tremendously, as the stock rallied 13.3% higher yesterday to reach a new high of $16.49 per share in yesterday's trading .
Stemline Therapeutics, Inc. to Present at the 12th Annual Healthcare Conference on May 1, 2013
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! NEW YORK, April 25, 2013 -- Stemline Therapeutics, Inc.
Stemline Therapeutics Reports Year-End 2012 Financial Results
Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells and tumor bulk, reported today its year-end 2012 financial results.
Stemline Therapeutics Receives New Coverage from Analysts at Aegis
The firm set a "buy" rating and a $35.00 price target on the stock. The analysts wrote, "In our view, Stemline Therapeutics represents a unique investment opportunity in the small-cap oncology arena, due to its proprietary knowledge base in the domain of cancer stem cells , its rapidly advancing clinical-stage pipeline, and its extremely ... (more)
Stemline Therapeutics, Inc. to Present at the 25th Annual Conference on March 20, 2013
Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells and tumor bulk, announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 25th Annual Roth Conference on Wednesday, March 20th, 2013 at 8:00AM PT.